CytomX Therapeutics, Inc. (CTMX) SEC Filings & Earnings Calls

Revenue decline due to completion of collaboration obligations; no approved products.

“Total revenue was $1.4 million for the quarter ended June 30, 2026, compared to $18.7 million for the second quarter of 2025. The decrease in revenue was driven primarily by the completion of the Company’s performance obligation during 2025 in the collaborations with Bristol Myers Squibb and lower research activities in the Astellas collaboration.” · word for word

Collaboration concentration risk

“Revenue is entirely dependent on collaborations; two major partners (Astellas, BMS) terminated in 2026.”

Clinical trial failure risk

“Product candidates are in early stages; no approved products.”

Dependence on Regeneron collaboration

“Regeneron now represents the primary source of deferred revenue and future potential milestones.”

Potential dilution from increased authorized shares and equity plan

“Authorized shares doubled from 300M to 600M; equity incentive plan increased by 6.5M shares”

Milestone payments are contingent on development success

“milestones covered under the scope of the Agreement are up to approximately $4 billion” · word for word

Collaboration dependency risk

“In the first quarter of 2026, Astellas chose not to advance the remaining preclinical programs and terminated the Astellas Agreement effective May 12, 2026.” · word for word

Revenue concentration risk

“Revenues $10,258 (2026) vs $50,917 (2025).”

Revenue highly dependent on collaborations; significant decline after completion of BMS and Amgen deals.

“Revenue decreased from $50.9M to $10.3M due to completion of performance obligations in collaborations.”

Clinical-stage company with no approved products; Varseta-M success critical.

“Varseta-M is the lead asset; FDA interactions planned; no approved products.”

Operating expenses increasing while revenue declining; cash burn rate.

“Operating expenses $29.9M vs revenue $10.3M; cash runway to 2H 2028.”

Dilution from authorized share increase

“If the Charter Amendment is approved, the additional 300,000,000 authorized shares of common stock will be identical in all respects to the shares of common stock currently authorized and outstanding.” · word for word

Ongoing equity dilution from compensation plans

“Our Compensation Committee has determined that these reserves would be insufficient to meet our operational needs over the next 1-2 year period and we are therefore requesting 6,500,000 additional shares to be approved for issuance under our Amended and Restated 2015 Plan.” · word for word

Net loss in 2025

“Net Income ($ Thousands): 2025 (20,370)”

High CEO pay relative to performance

“Compensation Actually Paid to PEO 1,2,3 ($): 2025 10,636,158” · word for word

Significant dilution: 45.99M new shares plus pre-funded warrants; potential overhang on stock price.

“45,990,567 shares of common stock and pre-funded warrants to purchase 1,179,245 shares issued.” · word for word

Clinical development risk

“Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability.” · word for word

Funding risk

“We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all.” · word for word

Safety risk

“On August 13, 2025, we announced that a single Grade 5 treatment-related acute kidney injury occurred in a patient with a complex medical history, including having a solitary kidney.” · word for word

Competition risk

“We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms.” · word for word

Revenue concentration risk from collaboration dependencies; Astellas termination reduces future collaboration revenue.

“Revenue decline driven by completion of BMS collaboration and lower performance completion estimates; Astellas collaboration terminated.”

Clinical development risk; Varseta-M and CX-801 are still in early stages with no approved products.

“Varseta-M Phase 1 dose expansion; CX-801 Phase 1 dose escalation; FDA alignment for registrational trial not yet achieved.”

Cash runway risk; despite current runway, ongoing R&D spend may require future financing.

“Cash runway to Q2 2027; operating expenses still significant at $98.6M annually.”

Collaboration Termination Risk

“In March 2025, CytomX and Amgen jointly decided to not continue CX-904 development and Amgen terminated its license to the EGFR Products.” · word for word

Revenue Concentration Risk

“Revenue is derived from a limited number of collaboration partners; termination of Amgen program and Moderna budget cuts reduce future revenue.”

Cash Burn Risk

“Net cash used in operating activities was $52.3M for the nine months ended September 30, 2025.”

Revenue decline from collaboration completions; dependency on pipeline success

“Revenue decrease driven primarily by completion of performance obligations in Bristol Myers Squibb collaboration and decrease in Moderna activities”

Cash burn rate; runway only to Q2 2027

“cash runway to the second quarter of 2027” · word for word

Program de-prioritization (CX-904) and restructuring executed

“reduction in CX-904 spend due to program de-prioritization in Q1 2025, reduced research expenses following the Q1 2025 restructuring” · word for word